88 During the past twenty years, new modalities for precision therapies, CRISPR gene editing, RNA therapeutics and targeted protein degradation have proliferated. Innovative therapies powered by artificial intelligence (AI), CRISPR gene editing, and new sequencing technologies have increased returns on research and development (R&D), while enabling undruggable targets to become druggable. S E PI A R E Increasingly, precision therapies are becoming multiomic and curative, with H T N mechanisms of action spanning DNA, RNA, proteins, and more. Based on ARK's O I S I C research, the enterprise value of companies focused on precision therapies could E PR appreciate 28% at an annual rate during the next seven years, from ~$820 billion in 2023 to ~$4.5 trillion by 2030. Sources: ARK Investment Management LLC, 2024. This ARK analysis is based on a range of external sources, which may be provided upon request. Forecasts are inherently limited and cannot be relied upon. For informational purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security. Past performance is not indicative of future results.